Tenax Therapeutics Inc expected to post a loss of $1.94 a share - Earnings Preview

Tenax Therapeutics

24/03/2023 21:20

* Tenax Therapeutics Inc  TENX.OQ   TENX.O  is expected
to show no
change in quarterly revenue when it reports  results on March 27
(estimated). 
    * 
    * ​Refinitiv's mean analyst estimate for Tenax Therapeutics
Inc is
for a loss of $1.94 per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Tenax
Therapeutics Inc is $80​, above​ its last closing price
of $0.53. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2022  -2.10       -2.10      -2.20     Missed  -4.8
 Jun. 30 2022  -1.80       -1.80      -2.20     Missed  -22.2
                                                        ​
 Dec. 31 2021              -3.20      -0.80     Beat    75
 ​​Sep.        -2.60       -2.60      -3.00     Missed  -15.4
 30 2021                                                
 Jun. 30 2021  -2.60       -2.60      -2.00     Beat    23.1​
 Mar. 31 2021  -4.20       -4.20      -32.80    Missed  -681
 Dec. 31 2020  -3.60       -2.80      -12.00    Missed  -328.6
 This summary was machine generated March 24 at 21:20 GMT.  All
figures in US dollars  unless otherwise stated